Your browser doesn't support javascript.
loading
Use of Midodrine in Heart Failure: Two Case Reports and a Review of the Literature.
Hajjiah, Adnan; Maadarani, Ossama; Bitar, Zouheir; Hanna, Boutros; Elshabasy, Ragab; Abdelfatah, Mohammad; Gohar, Mohammad.
Afiliação
  • Hajjiah A; Clinical Pharmacy Department, Ahmadi Hospital - Kuwait Oil Company, Al Ahmadi, Kuwait.
  • Maadarani O; Internal Medicine Department, Ahmadi Hospital - Kuwait Oil Company, Al Ahmadi, Kuwait.
  • Bitar Z; Internal Medicine Department, Ahmadi Hospital - Kuwait Oil Company, Al Ahmadi, Kuwait.
  • Hanna B; Internal Medicine Department, Ahmadi Hospital - Kuwait Oil Company, Al Ahmadi, Kuwait.
  • Elshabasy R; Internal Medicine Department, Ahmadi Hospital - Kuwait Oil Company, Al Ahmadi, Kuwait.
  • Abdelfatah M; Internal Medicine Department, Ahmadi Hospital - Kuwait Oil Company, Al Ahmadi, Kuwait.
  • Gohar M; Internal Medicine Department, Ahmadi Hospital - Kuwait Oil Company, Al Ahmadi, Kuwait.
Eur J Case Rep Intern Med ; 9(3): 003246, 2022.
Article em En | MEDLINE | ID: mdl-35402323
Hypotension in patients with heart failure is much more frequent in daily clinical practice than the 10-15% reported in clinical trials. In patients with heart failure with reduced ejection fraction (HFrEF), hypotension frequently limits the initiation and up-titration of guideline-directed medical therapy (GDMT). Midodrine is a peripheral alpha-1 agonist and a vasopressor anti-hypotensive agent approved for the treatment of orthostatic hypotension. We describe two cases where midodrine was prescribed in patients with HFrEF and hypotension. LEARNING POINTS: Hypotension in patients with systolic heart failure is a frequent presentation and can limit the initiation and optimization of guideline-directed medical therapy.Midodrine is a peripheral alpha-1 agonist and anti-hypotensive agent approved for the treatment of orthostatic hypotension.Midodrine may be used off-label in patients with heart failure with reduced ejection fraction (HFrEF) and symptomatic hypotension to allow optimization of medical therapy.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article